

Silvia Papa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1750592/publications.pdf>

Version: 2024-02-01

40
papers

975
citations

393982

19
h-index

454577

30
g-index

40
all docs

40
docs citations

40
times ranked

924
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 157, 376-383.	0.4	97
2	Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 642-652.	2.3	83
3	Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. <i>Rheumatology</i> , 2013, 52, 1525-1528.	0.9	67
4	Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 395-403.	0.3	66
5	Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. <i>International Journal of Cardiology</i> , 2013, 164, 323-326.	0.8	55
6	Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: Determinants and impact on pump function. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 381-389.	0.3	54
7	Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 1313-1322.	0.4	51
8	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 364-372.	0.3	50
9	Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 195-205.	0.3	46
10	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 484-492.	2.5	41
11	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2020, 301, 183-189.	0.8	40
12	Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 49, 1601419.	3.1	37
13	Pulmonary Arterial Dilatation in Pulmonary Hypertension: Prevalence and Prognostic Relevance. <i>Cardiology</i> , 2012, 121, 76-82.	0.6	36
14	The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 306-314.	0.3	32
15	Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 310-320.	0.3	31
16	Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 162-172.	2.3	29
17	Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1321-1329.	0.3	28
18	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1389-1397.	0.3	24

#	ARTICLE	IF	CITATIONS
19	Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2054-2056.	2.3	23
20	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. <i>Journal of Clinical Medicine</i> , 2021, 10, 619.	1.0	13
21	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 780-790.	0.3	13
22	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. <i>International Journal of Cardiology</i> , 2013, 167, 220-224.	0.8	12
23	Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. <i>International Journal of Cardiology</i> , 2018, 271, 301-305.	0.8	10
24	Intra-aortic balloon counterpulsation timing: A new numerical model for programming and training in the clinical environment.. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 194, 105537.	2.6	6
25	Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
26	The importance of right ventricular function in patients with pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 809-815.	1.0	4
27	Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 65-71.	0.8	4
28	Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 166-167.	0.3	3
29	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension. <i>Heart Failure Reviews</i> , 2023, 28, 745-755.	1.7	3
30	Ventricular and Atrial Pressureâ€”Volume Loops: Analysis of the Effects Induced by Right Centrifugal Pump Assistance. <i>Bioengineering</i> , 2022, 9, 181.	1.6	3
31	Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. <i>Respiratory Physiology and Neurobiology</i> , 2019, 264, 33-39.	0.7	2
32	Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 82.	1.0	2
33	Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , 2022, 145, 107024.	1.0	2
34	Letter to the editor about the paper â€œRight ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertensionâ€”by Murata et al.. <i>International Journal of Cardiology</i> , 2017, 234, 128.	0.8	1
35	Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up. <i>Journal of Clinical Medicine</i> , 2021, 10, 3008.	1.0	1
36	Right ventricular assessment matters for precision medicine. Reply to â€œIdentifying parameters associated with response to switching from a PDE5i to riociguat in RESPITEâ€” International Journal of Cardiology, 2021, 333, 210.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. International Journal of Cardiology, 2021, 332, 193-194.	0.8	0
38	The Authors Reply. JACC: Cardiovascular Imaging, 2021, 14, 1488-1489.	2.3	0
39	The effects of cardiovascular diseases and treatment on clinical course of hospitalized COVID-19 patients. European Heart Journal Supplements, 2021, 23, .	0.0	0
40	Follow-up of hospitalized COVID-19 survivors: assessment of short- and long-term cardiovascular sequelae after SARS-CoV-2 infection. European Heart Journal Supplements, 2021, 23, .	0.0	0